This post summarises OHE’s activities at the upcoming HTAi meeting in Oslo, June 2015. Topics include the effect of NICE decisions abroad, a framework for developing formularies in MICs, a new drug development paradigm, and a comparison of EQ-5D-5L and EQ-5D-3L.
HTAi’s 12th Annual Meeting, Global Efforts in Knowledge Transfer: HTA to Health Policy and Practice, is scheduled for 15-17 June 2015 in Oslo. Members of the OHE team will be attending and presenting key research. Scheduled presentations are summarised below.
New Clinical Development Paradigm for Drugs
Sean Tunis (Center for Medical Technology Policy: CMTP), Adrian Towse (OHE), Sarah Garner (NICE Franz Pichler (Eli Lilly).
This workshop combines knowledge from two projects: (i) the New Drug Development Project, undertaken by CMTP and OHE, funded by five companies, which set out development pathways for different drug ‘archetypes’ and (ii) initial findings from the Innovative Medicines Initiative (IMI) ‘GetReal’ Project proposing innovative (more pragmatic) trial designs in pre-and post-launch drug development. The target audience includes drug developers, clinical trial reviewers and methodologists, HTA evidence assessors, HTA decision makers. The objective is to share knowledge about the likely changes in the type of evidence that is generated in the drug development process and the impact that HTA bodies can have on that process.
Sunday 14 June, 1:30 PM
Workshop ID: 14
A Decision Making Framework for Developing Formularies in Middle Income Countries
Karla Hernández-Villafuerte (OHE), Martina Garau (OHE), Adrian Towse (OHE), Lou Garrison (University of Washington), Simrun Grewal (University of Washington), David Grainger (Eli Lilly).
This presentation outlines the methodology and preliminary findings of our work to develop recommendations on the methods and processes for identifying medicines for national formularies in middle income countries (MICs). It explores potential links between “macro-level” decision-making (approaches to designing and organizing the health system) and “micro-level” decision-making (related to decisions on individual health technologies).
Preliminary findings show that the existing literature explores issues related to health systems strengthening and decision making on coverage of individual health technologies separately. Approaches to formulary decisions need to explore how to combine treatment-specific factors (e.g., clinical effectiveness), with factors related to health system design (e.g., disease priorities) and financing (including affordability).
Tuesday 16 June, 2:00 PM
Room: OS25 Film Section, Oral ID: 230
Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?
This presentation compares the two versions of the EQ-5D for use in adult populations, one with 3 response levels in each of the instrument’s 5 dimensions (EQ-5D-3L) and one with 5 levels (EQ-5D-5L).
EQ-5D-5L data were available from 996 respondents selected at random from residential postcodes who took part in the EQ-5D-5L value set for England study. EQ-5D-3L data were available from 7,294 participants included in the 2012 Health Survey for England. Responses on the 3L and 5L versions were compared by comparing score distributions on the two versions, both in terms of the profile (dimensions) and the EQ-VAS. We analysed health status reporting on the descriptive profile, EQ-Index, and EQ-VAS of both versions of EQ-5D by age, sex, and educational background. We used χ^2 to test for differences between respondent categories when analyzing EQ-5D profile data and the t test when analyzing EQ-5D Index and VAS scores.
Our preliminary results suggest that the expanded 5L version of EQ-5D may be a more useful instrument for the measurement of health status in population health surveys than the 3L version.
Monday 15th June, 16:30
Room: Oslofjord room, Oral ID: 392
Do NICE Decisions Affect Decisions in Other Countries?: A Feasibility Study
This poster looks at whether NICE recommendations on the use of a new drug affect recommendations from other bodies in countries outside England and Wales. A basket of 29 drug/indication pairs and a group of 15 countries were studied (Australia, Canada, Denmark, France, Italy, Korea, Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia, Ecuador, Egypt and Ghana). Information regarding NICE HTA recommendations was extracted from NICE’s website and HTAinSite.com, and additional information collected via official websites and an online-survey of key opinion leaders from the countries under study. The findings suggest that after the publication of a NICE appraisal there is a higher probability that an HTA is undertaken for the same drug in other countries. The results suggest that the selected agencies are considering NICE decisions as a factor for rejecting or restricting the use of drugs which in other case would be recommended or reimbursed.
Wednesday 17 June, 11:00 AM
Poster Meeting Station A, Poster ID: 263
